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Abstract
Recently, a meta-analysis, including 26 526 laboring vertex singletons at term, summarized all
available level-1 data from six high-quality randomized clinical trials (RCTs) on the use of ST
analysis (STAN) during labor as an adjunct to conventional intrapartum fetal heart rate
monitoring. The meta-analysis showed that STAN did not improve perinatal outcomes or
decrease cesarean deliveries. Nonetheless, there are still reasons to believe STAN may have a
role in the future research on intrapartum fetal monitoring. Out of six trials included in the
meta-analysis, two included all cephalic singletons in labor, and four enrolled only high-risk
pregnant women. This combination of both low- and high-risk populations may have distorted
the potential impact of STAN. The test for heterogeneity between both subgroups was found
to be statistically significant, indicating that the effect of STAN was different in high-risk women
compared to a combination of both low- and high-risk women. Furthermore, the classifications
of the fetal heart rate patterns used in the included randomized trials were different. Last but
not least, despite426 000 women with singleton gestations were included in the meta-analysis,
the evidence still suffers from a lack of power, especially for subgroup analyses. In summary,
while the level-1 data so far indicate overall no perinatal benefit of adding STAN to
conventional intrapartum fetal heart rate monitoring for the outcomes most of interest, several
issues point to the fact that more research is needed before the STAN technology can be
deemed of no value for fetal monitoring in labor.
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Recently, we published a meta-analysis [1], summarizing all
available level-1 data from six high-quality randomized
clinical trials (RCTs) on the use of ST analysis (STAN)
during labor in term singleton gestations as an adjunct to
conventional intrapartum fetal heart rate monitoring (i.e.
cardiotocography) [2–7]. The meta-analysis included 26 529
laboring vertex singletons at term and showed that STAN did
not improve perinatal outcomes or decrease cesarean
deliveries compared to cardiotocography (CTG) alone.
Nonetheless, there are still reasons to believe STAN may
have a role in future research and clinical care.
First: heterogeneity in inclusion criteria among trials
The incidence of cerebral palsy is about 2 in 1000 live births,
and today approximately 10% of cerebral palsy cases are
believed to be related to intrapartum asphyxia [8]. Given the
very low incidence of this adverse outcome some RCTs
adopted the strategy to analyze women with higher risk of
intrapartum fetal hypoxia. Out of six RCTs on STAN included
in the meta-analysis [1], two included all cephalic singletons
in labor [4,7], and three enrolled pregnant women with high
risk conditions such as maternal disease, prior obstetric
complications, hypertensive disorders, intrauterine growth
restriction, ruptured membranes for more than 24 h, postdates
gestational age, failure to progress, need for pain relief,
meconium-stained amniotic fluid or non-reassuring fetal heart
rate (NRFHR) [2,3,6]. The French RCT included only women
with abnormal CTG in labor with or without meconium-
stained amniotic fluid [5]. This combination of both low- and
high-risk populations may have distorted the potential impact
of STAN found in the meta-analysis. When limiting the
analysis to RCTs including only high-risk pregnant women
(11 515 singletons included) [3–6], the use of the STAN
showed a non-significant reduction by 27% in perinatal
composite outcome (1.5% versus 2.0%; RR 0.73, 95% CI
0.53–1.00). When limiting the analysis to RCTs including
both low- and high-risk women [4,7], no such effect was
found (RR 1.14, 95% CI 0.85–1.53). In fact the test for
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heterogeneity between both subgroups was found to be
statistically significant (p¼ 0.04), indicating that the effect of
STAN was different in high-risk women compared to a
combination of both low- and high-risk women. Future meta-
analysis using individual participant data from all studies may
clarify whether STAN may be beneficial in a subgroup of
high-risk women in labor of a singleton in cephalic
presentation.
Second: learning curve
The STAN methodology depends on visual interpretation of
the CTG trace [9]. Many observational studies investigating
the effects of long-term use of STAN have confirmed that
training and experience do improve the interpretation of the
fetal heart rate patterns, leading to a decrease in the metabolic
acidosis rate [10–13]. Evidence for an existing learning curve
differed between trials included in the meta-analysis. The
Swedish trial did find a difference between the first and
second part of the trial [3]. The American RCT found no
training effect which might be due to the low inclusion rate
[7]. With most centers including only a few patients per
month learning and experience with STAN seems hard to
achieve. The remaining included trials have not investigated
their learning curve. Using individual participant data from all
trials, a subgroup analysis of the centers with highest
inclusion rates would be of interest to further elucidate on
this point.
Third: Hawthorne effect
Another possible explanation for the negative findings of
some trials and consecutive meta-analyses [1,2,4–7], may be
the change in behavior due to a subjects’ awareness of being
observed, called the Hawthorne effect [14]. The Hawthorne
effect is actually a threat to the accuracy of any study
collecting data via direct observation [15]. This phenomenon
has four characteristics: 1. It is time dependent, which means
that the magnitude and direction of the behavioral change
depends on the total time practitioners using STAN are aware
of being observed; 2. It has a performance ceiling, so the
influence of the effect grows over time until reaching an upper
limit; 3. Its impact decreases over time after peak perform-
ance; 4. Last but not least, behavior change occurs always
after practitioners become aware of being watched [16]. It is
reasonable to hypothesize that at least in the first part of some
of the trials, practitioners’ performance and previous experi-
ence with CTG but not with STAN might have improved the
outcomes in the CTG arm, thereby limiting the effect of
additional ST information in comparison to CTG alone. In the
second part of the trials the Hawthorne effect, which is time
dependent and decreases after the peak performance, might
have reduced its influence on practitioners, allowing a more
realistic comparison between CTG and STAN + CTG. In the
Swedish RCT, a very obvious change occurred in the CTG
arm over time and it was hypothesized that with increasing
trust in the addition of STAN, the trust with CTG decreased,
leading to an increase in operative labor in the CTG arm
compared to the CTG + ST arm [3]. Again a subgroup
analysis in centers where the inclusion rate permitted
learning, would possibly share some light on this perspective.
Fourth: CTG three versus four tier classification
European RCTs used a four-tier classification of the fetal
heart rate pattern. Belfort et al. [7], however, did not follow
this system since the FDA had approved only the three-tier
system. This is a crucial difference among trials which
directly influences the clinical behavior, and thus the effect on
outcome. In the four tier system classification, the NRFHR
pattern has been subdivided in two CTG categories (inter-
mediate and abnormal), thus modulating the cut offs of the
different ST events, in order to discriminate NRFHR patterns
needing intervention from those not needing intervention
[17]. From intermediate to abnormal category the intervention
cutoffs of ST events decrease, which means that the worse the
CTG trace, the lower the value of ST event (if it occurs)
suggesting clinical intervention. With only one category of
NRFHR CTG, as in the three-tier classification, these
gradations are not present, and intervention may be therefore
advocated in situations where it could be avoided. A
prospective observational study has demonstrated that the
inter-observer agreement on classification of the intrapartum
CTG is poor, especially in case of intermediary or abnormal
CTG traces, and that the addition of fetal STAN led clinicians
to decide whether to intervene or not in a more standardized
way [18]. In fact, in the meta-analysis a statistically non-
significant 21% decrease in perinatal composite outcome was
found when analysis was limited to RCTs using only four-tier
system (n ¼12 987) for the STAN (1.5% versus 1.9%; RR
0.79, 95% CI 0.61–1.03). This effect was not statistically
different (p¼ 0.09) from the effect of STAN found in the
study of Belfort et al. that used a tree-tier system (RR 1.14,
95% CI 0.83–1.57), however, given the effect estimates
in both subgroups a differential effect could not be
excluded [19].
Fifth: power
Despite 426 000 women with singleton gestations were
included in the six RCTs, the evidence still suffers from a
lack of power, especially for subgroup analyses related to
study population and the system for STAN. To the future
mother and her obstetrician or midwife, probably the most
important outcome would be an improvement in neonatal
outcome, e.g. the primary outcome of adverse composite
perinatal outcome (intrapartum fetal death, neonatal death,
Apgar score  3 at 5 min, neonatal seizure, metabolic
acidosis, intubation for ventilation at delivery, or neonatal
encephalopathy), and in particular in neonatal metabolic
acidosis, which predicts later childhood function [20].
Our meta-analysis found an overall non-significant decrease
by 26% in neonatal metabolic acidosis (0.5% versus 0.7%; RR
0.74, 95% CI 0.54–1.02). With an a of 0.05 and 80% power
for all these following analyses, a sample size of about 29 316
patient is required, pointing to a type II error. The number of
unselected women needed to screen by any STAN system to
prevent a case of neonatal metabolic acidosis is about 545.
When analysis is restricted to only high-risk women, a sample
size of about 11 079 high-risk women is required, pointing to
the fact that a few more of these women enrolled in the RCTs
would have made results significant. The number of high-risk
women needed to screen by STAN to prevent a case of
DOI: 10.1080/14767058.2016.1247263 STAN might not be dead 2307
composite perinatal outcome is about 205. When analysis is
restricted to only four-tier STAN system, a sample size of
about 16 613 women is required, pointing again to a type II
error. The number of unselected women needed to screen by
four-tier system STAN to prevent a case of composite
perinatal outcome is about 250.
In summary, while the level 1 data so far indicate no perinatal
benefit of adding STAN to conventional intrapartum fetal heart
rate monitoring for the outcomes most of interest, several issues
point to the fact that more research (e.g. trials focusing on high-
risk pregnancies) is needed before the STAN technology can be
deemed of no value for fetal monitoring in labor.
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